Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326826 | 0.87 | ACACB (0.35) | ACACBCYP3A4GPR119SCN9AMET | |
| SCHEMBL21470682 | 0.81 | HDAC8 (0.37) | — | |
| SCHEMBL21470769 | 0.79 | HTR6 (0.41) | GPR119NAMPT | |
| SCHEMBL21470423 | 0.76 | ESR2 (0.41) | ACACBGPR119METESR2NR1H2 | |
| SCHEMBL23327025 | 0.76 | MET (0.32) | MET | |
| SCHEMBL21470633 | 0.72 | NR1H2 (0.38) | GPR119ESR2NR1H2NAMPT | |
| SCHEMBL21593114 | 0.70 | NR1H2 (0.44) | ACACBCYP3A4GPR119ESR2NR1H2 | |
| SCHEMBL21470634 | 0.70 | ESR2 (0.48) | GPR119ESR2NR1H2NAMPT | |
| SCHEMBL23353521 | 0.70 | MET (0.32) | ACACBCYP3A4METAXLESR2 | |
| SCHEMBL23326814 | 0.70 | ABHD6 (0.33) | METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019200120-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | LYCERA CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |